Sopharma

New equity research report: Sopharma’s recovery is speeding up

Sopharma, the leading generic pharmaceutical company in Bulgaria, is recovering faster than expected from the Russia/Ukraine conflict on strong exports – this was concluded in the latest equity research report by ELANA Trading analysts covering Q1 2017 earnings of Sopharma. Sopharma’s top line recovery speeding up Sopharma’s top line is recovering faster than ELANA Trading’s… Read more

Ognyan Donev, CEO Sopharma

CEO Ognyan Donev ups his stake in Sopharma

CEO Ognyan Donev controlled key shareholder in Sopharma (3JR BU) ups his stake in the company, according to a regulatory filing. Donev Investments Holding has acquired 503 000 shares or 0.37% of the share capital, according to the filing. Post the transaction Donev Investments Holding’s stake has increased to 25.15%. Sopharma’s key holding structure acquires… Read more

Roadshow: Bulgarian Capital Market Day in London on 18 May 2017

A special Bulgarian Capital Market Day for CEE-focused investors will take place at EBRD headquarters on 18 May 2017 presenting for one day an insight in CEE regional development and Bulgarian capital market in-depth.
Sopharma

New research report: Sopharma finally catches the tailwinds

Sopharma – the leading generic pharmaceutical company in Bulgaria – booked a 2016 performance in line with ELANA Trading analysts’ expectations. Top line negative surprises seem fading away, operating profits sustained on cost optimization and profitable divestments made the bottom line. Sales in line with analysts’ expectations After losing a quarter of its operations due… Read more

A glimpse on audit impact on financial statements FY 2016

Audit ups Speedy’s (0SP BU) unconsolidated net income by 20% to BGN 7.7m, according to the Company’s audited unconsolidated FY2016 financial statements published at the end of March 2017. Audited net income stands at BGN 7.7m, up 20% vs. preliminary announced result of BGN 6.4m. The latter is due mostly on 24% lower depreciation expense… Read more

Bulgarian stocks book best Q1 since the start of 2014

The main index of Bulgarian stocks SOFIX added 8.11% q/q in 1Q17, best performance since the start of 2014. The index booked fourth consecutive quarter on the upside adding 43% since the last down quarter – 3Q16. Generic drug pharma company Sopharma (3JR BU) contributed most to SOFIX’ performance over the quarter, adding 31% q/q… Read more

ELANA Trading has a 29 years of history on financial markets, offering a wide range of services and markets. ELANA Trading quality service has been recognized by 24 industry awards. The broker is part of the international brokers’ network of US Auerbach Grayson & Co. since 1998 and maintains long-term partnerships with a lot of international financial institutions.

ELANA Trading is part of ELANA group - one of the largest groups in the non-banking financial sector in Bulgaria.

Contacts

Dimitar Georgiev
Head of Trading
Phone: +359 (2) 81 000 25
Email: georgievd@elana.net

Tatyana Puncheva-Vasileva
Head of Research
Phone: +359 (2) 81 000 24
Email: vasileva@elana.net

Contacts

Sopharma Business Towers,
Tower B, Floors 12-13,
5, Lachezar Stanchev St,
1797 Sofia, Bulgaria

Phone: +359 (2) 81 000 25
Phone: +359 (2) 81 000 26
Email: bgtrader@elana.net
Disclaimer: This website represents ELANA Trading with the sole purpose to provide information. The data published on the website is not provided to be used as a background for specific investment decisions. No publication of ELANA Trading should be construed as an offer (or solicitation of an offer) to U.S. persons to buy or sell financial instruments or any financial product, make any investment or participate in any particular trading strategy (collectively “Offers”). No Publication of ELANA Trading should be construed as an Offer (or solicitation of an offer) in any jurisdiction in which such Offer would be illegal. Any such perceived Offer will not be honoured by ELANA Trading.

© 1991 - 2024 ELANA | ELANA Trading Privacy policy Manage cookie consent